ClinicalTrials.gg
Sign In

Hemangiosarcoma clinical trials

The registry lists 99 studies for Hemangiosarcoma across more than 10 countries. 16 are recruiting or about to start. 39 of them are mainly about Hemangiosarcoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-03.

Get an email when these change. Save the Hemangiosarcoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
55
Recruiting
15
Terminated
9
Active, not recruiting
7
Status unknown
7
Withdrawn
5

Phase

Phase 2
62
Phase 1
18
Phase 3
13
Phase 4
1

Where

United States
49
France
18
United Kingdom
18
Belgium
11
Germany
11
Denmark
11

Who runs them

European Organisation for Research and Treatment of Cancer - EORTC (14) · National Cancer Institute (NCI) (10) · M.D. Anderson Cancer Center (5) · Centre Oscar Lambret (3) · Memorial Sloan Kettering Cancer Center (3) · Children's Oncology Group (3) · Tracon Pharmaceuticals Inc. (2) · Brown University (2)

What is being tested here

Drugs under test in Hemangiosarcoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Pembrolizumab202
Doxorubicin158
Ifosfamide168
Pazopanib104
Propranolol103
Durvalumab102
Cemiplimab102
Regorafenib102
Vusolimogene oderparepvec101
Selinexor101

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3 open · Immune checkpoint inhibitors 3 open · Alkylating agents 1 open · Antimitotic agents 8 · Angiogenesis inhibitors 6

Coming up

0phase 3 studies under way
5studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 5

Who these studies take

Of the 15 Hemangiosarcoma studies recruiting now, 10 (67%) set no upper age limit and 4 (27%) stop at 75 or younger. 4 (27%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 15
AgeWomenMen
103 (20%)3 (20%)
1815 (100%)15 (100%)
3015 (100%)15 (100%)
4014 (93%)14 (93%)
5014 (93%)14 (93%)
6514 (93%)14 (93%)
7512 (80%)12 (80%)
8511 (73%)11 (73%)

Across all 99 studies, recruiting or not: 21% stop at 75 or younger and 11% at 65; 35% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hemangiosarcoma studies take

Of 28 phase 2 interventional studies under Hemangiosarcoma, half reached primary completion within 64 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 264 mo45–91 · 28 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 99. Browse all 99 → or search them.